PARP1 and cancer: Recently, Hirai et al. determined that treatment of MIA PaCa-2 cell line by olaparib before proton irradiation enhanced radiosensitization, specifically in the SOBP region, compared to the entrance region, thus demonstrating that PARP inhibition radiosensitized cancer cells in a LET-dependent manner [16].